Profarma Distribuidora de Produtos Farmacêuticos Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Profarma Distribuidora de Produtos Farmacêuticos.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Healthcare earnings growth | 26.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Has A Somewhat Strained Balance Sheet
Dec 19
Returns On Capital Are Showing Encouraging Signs At Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3)
Nov 02Shareholders Will Be Pleased With The Quality of Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Earnings
Aug 14Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) 28% Price Boost Is Out Of Tune With Earnings
Mar 01These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Feb 21Returns On Capital Are Showing Encouraging Signs At Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3)
Nov 04Investors Will Want Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Growth In ROCE To Persist
Aug 03These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Jun 08These 4 Measures Indicate That Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Using Debt Extensively
Sep 26Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Shares Fly 26% But Investors Aren't Buying For Growth
Jan 01Here's Why Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Is Weighed Down By Its Debt Load
May 28Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Might Have The Makings Of A Multi-Bagger
May 07How Much Of Profarma Distribuidora de Produtos Farmacêuticos S.A. (BVMF:PFRM3) Do Institutions Own?
Mar 10Are Profarma Distribuidora de Produtos Farmacêuticos' (BVMF:PFRM3) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 02
Is Profarma Distribuidora de Produtos Farmacêuticos (BVMF:PFRM3) Using Too Much Debt?
Jan 05What Type Of Shareholders Make Up Profarma Distribuidora de Produtos Farmacêuticos S.A.'s (BVMF:PFRM3) Share Registry?
Dec 10In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Profarma Distribuidora de Produtos Farmacêuticos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 9,345 | 107 | 351 | 469 | N/A |
| 6/30/2024 | 9,038 | 91 | 468 | 571 | N/A |
| 3/31/2024 | 8,889 | 77 | 234 | 323 | N/A |
| 12/31/2023 | 8,662 | 70 | 179 | 261 | N/A |
| 9/30/2023 | 8,550 | 47 | 310 | 385 | N/A |
| 6/30/2023 | 8,291 | 31 | 221 | 292 | N/A |
| 3/31/2023 | 8,087 | 82 | 279 | 349 | N/A |
| 12/31/2022 | 7,816 | 81 | 56 | 126 | N/A |
| 9/30/2022 | 7,435 | 87 | 58 | 119 | N/A |
| 6/30/2022 | 7,031 | 96 | -117 | -50 | N/A |
| 3/31/2022 | 6,661 | 63 | -61 | 20 | N/A |
| 12/31/2021 | 6,413 | 78 | 25 | 108 | N/A |
| 9/30/2021 | 6,199 | 95 | -161 | -82 | N/A |
| 6/30/2021 | 5,891 | 99 | -336 | -267 | N/A |
| 3/31/2021 | 5,579 | 60 | -33 | 18 | N/A |
| 12/31/2020 | 5,481 | 52 | -6 | 39 | N/A |
| 9/30/2020 | 5,281 | 44 | 76 | 114 | N/A |
| 6/30/2020 | 5,218 | 16 | 119 | 150 | N/A |
| 3/31/2020 | 5,104 | 21 | 42 | 69 | N/A |
| 12/31/2019 | 4,801 | 12 | 100 | 128 | N/A |
| 9/30/2019 | 4,677 | -5 | 60 | 85 | N/A |
| 6/30/2019 | 4,513 | -13 | -18 | 5 | N/A |
| 3/31/2019 | 4,388 | -12 | -86 | -65 | N/A |
| 12/31/2018 | 4,271 | -10 | -71 | -56 | N/A |
| 9/30/2018 | 4,066 | -37 | -100 | -81 | N/A |
| 6/30/2018 | 4,009 | -65 | N/A | -22 | N/A |
| 3/31/2018 | 4,046 | -91 | N/A | -61 | N/A |
| 12/31/2017 | 4,101 | -113 | N/A | -52 | N/A |
| 9/30/2017 | 4,223 | -126 | N/A | 7 | N/A |
| 6/30/2017 | 4,195 | -100 | N/A | 54 | N/A |
| 3/31/2017 | 4,149 | -67 | N/A | -63 | N/A |
| 12/31/2016 | 4,085 | -49 | N/A | -107 | N/A |
| 9/30/2016 | 3,858 | -18 | N/A | -84 | N/A |
| 6/30/2016 | 3,780 | -14 | N/A | -95 | N/A |
| 3/31/2016 | 3,619 | -23 | N/A | -14 | N/A |
| 12/31/2015 | 3,465 | -21 | N/A | 59 | N/A |
| 9/30/2015 | 3,471 | -34 | N/A | 1 | N/A |
| 6/30/2015 | 3,392 | -48 | N/A | -82 | N/A |
| 3/31/2015 | 3,430 | -46 | N/A | 11 | N/A |
| 12/31/2014 | 3,449 | -52 | N/A | 59 | N/A |
| 9/30/2014 | 3,439 | -37 | N/A | 52 | N/A |
| 6/30/2014 | 3,455 | -11 | N/A | 73 | N/A |
| 3/31/2014 | 3,456 | 0 | N/A | 53 | N/A |
| 12/31/2013 | 3,470 | 20 | N/A | -90 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if PFRM3's forecast earnings growth is above the savings rate (10.4%).
Earnings vs Market: Insufficient data to determine if PFRM3's earnings are forecast to grow faster than the BR market
High Growth Earnings: Insufficient data to determine if PFRM3's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if PFRM3's revenue is forecast to grow faster than the BR market.
High Growth Revenue: Insufficient data to determine if PFRM3's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PFRM3's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 00:34 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Profarma Distribuidora de Produtos Farmacêuticos S.A. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Diego Moreno | BofA Global Research |
| Guilherme Assis | Brasil Plural |
| Joao dos Santos | BTG Pactual |